HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suhendan Ekmekcioglu Selected Research

interleukin-24 (ST16)

2/2011IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
12/2008Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
2/2007Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.
12/2006Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes.
1/2005Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
12/2004Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
2/2002Loss of MDA-7 expression with progression of melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Suhendan Ekmekcioglu Research Topics

Disease

43Melanoma (Melanoma, Malignant)
05/2022 - 02/2002
43Neoplasms (Cancer)
05/2022 - 02/2002
4Neoplasm Metastasis (Metastasis)
12/2020 - 02/2002
3Inflammation (Inflammations)
10/2013 - 11/2011
3Breast Neoplasms (Breast Cancer)
02/2007 - 10/2002
2Hypoxia (Hypoxemia)
10/2016 - 08/2014
2Disease Progression
05/2016 - 05/2004
1Colitis
01/2022
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2022
1Enterocolitis
01/2022
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/2017
1Wilms Tumor (Wilm's Tumor)
01/2017
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2017
1Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2017
1Adenocarcinoma
10/2016
1Carcinogenesis
05/2016
1Circulating Neoplastic Cells
07/2014
1Hypertension (High Blood Pressure)
07/2014
1Hemorrhage
07/2014
1Septic Shock (Toxic Shock Syndrome)
04/2014
1Idiopathic Pulmonary Fibrosis
04/2014
1Tuberous Sclerosis (Bourneville's Disease)
02/2014
1Necrosis
04/2013
1Chronic Renal Insufficiency
01/2013
1Lung Neoplasms (Lung Cancer)
02/2011

Drug/Important Bio-Agent (IBA)

18Proteins (Proteins, Gene)FDA Link
01/2021 - 06/2002
11Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
01/2021 - 01/2003
11Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2021 - 10/2002
8CytokinesIBA
01/2017 - 05/2004
7interleukin-24 (ST16)IBA
02/2011 - 02/2002
4Macrophage Migration-Inhibitory FactorsIBA
05/2022 - 11/2015
4InterferonsIBA
01/2022 - 07/2008
4Nitric Oxide Synthase (NO Synthase)IBA
01/2017 - 10/2002
4Interleukin-10 (Interleukin 10)IBA
02/2007 - 05/2004
3Interleukin-6 (Interleukin 6)IBA
01/2022 - 12/2006
3Biological ProductsIBA
01/2022 - 01/2005
3Messenger RNA (mRNA)IBA
01/2021 - 11/2011
3LigandsIBA
11/2015 - 12/2004
3EnzymesIBA
04/2014 - 09/2008
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
04/2013 - 10/2002
3InterleukinsIBA
11/2011 - 02/2007
2Oncogene Proteins (Oncogene Protein)IBA
01/2021 - 01/2017
2Small Interfering RNA (siRNA)IBA
01/2021 - 02/2014
2AntigensIBA
01/2021 - 01/2017
2Phosphotransferases (Kinase)IBA
01/2021 - 08/2014
2Arginine (L-Arginine)FDA Link
01/2018 - 01/2013
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2017 - 08/2014
2VemurafenibIBA
10/2016 - 10/2012
23-nitrotyrosineIBA
08/2014 - 09/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2014 - 07/2014
2Interleukin-1 (Interleukin 1)IBA
10/2012 - 11/2011
2Cisplatin (Platino)FDA LinkGeneric
03/2010 - 03/2005
2interleukin-20 receptorIBA
02/2007 - 12/2004
1CTLA-4 AntigenIBA
01/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021
1Programmed Cell Death 1 ReceptorIBA
01/2021
1AntibodiesIBA
01/2021
1PTEN Phosphohydrolase (PTEN Phosphatase)IBA
01/2021
1Prostaglandin-E SynthasesIBA
01/2019
13- (2,4- dichloro- 5- methoxyphenyl)- 2- sulfanyl- 4(3H)- quinazolinoneIBA
09/2018
1Dynamins (Dynamin)IBA
09/2018
1CitrullineIBA
01/2018
1OrnithineIBA
01/2018
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
03/2017
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2017
1Peptides (Polypeptides)IBA
01/2017
1Pharmaceutical PreparationsIBA
10/2016
14- (benzo(b)thiophen- 2- yl)- 3- bromo- 5- hydroxydihydrofuran- 2(3H)- oneIBA
05/2016
1Dinoprostone (PGE2)FDA Link
05/2016
1Formaldehyde (Formol)FDA Link
08/2014
1ParaffinIBA
08/2014
1NitratesIBA
07/2014
1cediranib (AZD2171)IBA
07/2014
1Bevacizumab (Avastin)FDA Link
07/2014
1OxidesIBA
07/2014
1GTP Phosphohydrolases (GTPases)IBA
02/2014
1trans-sodium crocetinate (crocetin)IBA
02/2014
1DNA AdductsIBA
10/2013
1LipidsIBA
10/2013
1Oxidants (Oxidizing Agents)IBA
10/2013
1Reactive Nitrogen SpeciesIBA
10/2013
1AntioxidantsIBA
10/2013
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
04/2013
1TWEAK ReceptorIBA
04/2013
1Indicators and Reagents (Reagents)IBA
04/2013
1Cell Surface ReceptorsIBA
04/2013
1Immunotoxins (Immunotoxin)IBA
04/2013
1Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA
01/2013
1bardoxolone methylIBA
01/2013
1Interleukin-1alpha (Interleukin 1 alpha)IBA
10/2012
1Neoplasm Antigens (Tumor Antigens)IBA
10/2012
1ChemokinesIBA
08/2012
1Neutralizing AntibodiesIBA
11/2011
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
11/2011
1Caspase 9IBA
02/2011
1Caspase 3 (Caspase-3)IBA
02/2011
1Tyrosine Kinase InhibitorsIBA
02/2011

Therapy/Procedure

17Therapeutics
01/2021 - 02/2002
9Immunotherapy
01/2022 - 11/2015
2Drug Therapy (Chemotherapy)
03/2010 - 12/2008